Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indonesia’s Top Pharma Kalbe To Build Its First In-country Plant For Cancer Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Kalbe Farma PT forecasts strong growth in 2013 as the cash-rich company gears up for the start of universal health coverage in 2014.

You may also be interested in...



Mixed Impact From Indonesian Foreign Ownership Changes?

A new economic stimulus package from the Indonesian government that includes allowing up to 100% foreign ownership in the pharmaceutical and health sectors has been welcomed by the multinational industry.

Indonesian Insurance Scheme ‘Not Sharia-Compliant’, Muslim Body Says

An edict by a top Muslim council in Indonesia that the country’s national health insurance does not follow Islamic sharia law principles has sparked debate in the world’s most populous Muslim-majority country.

Indonesia’s Struggling Insurance Operator Eyes Premium Rise

Indonesia’s national health insurance operator is seeking an increase in premiums as it struggles with deficits amid soaring claims within the system.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel